<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996459</url>
  </required_header>
  <id_info>
    <org_study_id>GWK-2020-06</org_study_id>
    <nct_id>NCT04996459</nct_id>
  </id_info>
  <brief_title>Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Real-world Study of Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose: To evaluate the efficacy and safety of Tislelizumab in combination with&#xD;
      advanced hepatocellular carcinoma in the real world; Study design: Non-intervention, single&#xD;
      center, case registration, real-world study; Number of registrations: 40;&#xD;
&#xD;
      Source of data: This project is a non-interventionary real world case follow-up registration.&#xD;
      All registration data are from real clinical practice cases. The collected data include the&#xD;
      following requirements:&#xD;
&#xD;
        1. Age ≥18 years old;&#xD;
&#xD;
        2. Unresectable hepatocellular carcinoma confirmed by histological examination or clinical&#xD;
           diagnosis;&#xD;
&#xD;
        3. Plan or have received systemic therapy combined with Tiralizumab;&#xD;
&#xD;
        4. No participation in other clinical studies;&#xD;
&#xD;
        5. Access to Tislelizumab treatment and other clinical records; Primary endpoint: Overall&#xD;
           response rate; Secondary endpoint: Disease control rate, progress free survival, overall&#xD;
           survival, safety; Exploratory endpoint: To explore the predictive value of multiple&#xD;
           Biomarker combinations, such as PD-L1, TMB, MSI, DDR, POLE/POLD, in HCC immunotherapy&#xD;
           response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress free survival</measure>
    <time_frame>6 weeks</time_frame>
    <description>progress free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 weeks</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (the incidence of adverse events and serious adverse events)</measure>
    <time_frame>3 weeks</time_frame>
    <description>the incidence of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tislelizumab group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab 200mg iv q3w</description>
    <arm_group_label>Tislelizumab group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients registrated and treated with Tislelizumab at least once were included in the&#xD;
        efficacy analysis population as well as the safety analysis population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        This project is a non-interventionary real world case follow-up registration. All&#xD;
        registration data are from real clinical practice cases. The collected data include the&#xD;
        following requirements:&#xD;
&#xD;
          1. Age ≥18 years old;&#xD;
&#xD;
          2. Unresectable hepatocellular carcinoma confirmed by histological examination or&#xD;
             clinical diagnosis;&#xD;
&#xD;
          3. Plan or have received systemic therapy combined with Tislelizumab;&#xD;
&#xD;
          4. No participation in other clinical studies;&#xD;
&#xD;
          5. Access to Tislelizumab treatment and other clinical records.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>FUSCC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Lu Wang, MD, PhD</investigator_full_name>
    <investigator_title>Head of liver surgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

